Market accessOfficial

AIFA activates web monitoring registry for ZIIHERA in HER2-positive biliary tract cancer

🇮🇹 AIFA · Thu 19 Nov 2026

From 19 November 2026, Italian centres can use zanidatamab through AIFA's monitoring registry for the one indication admitted to reimbursement.

The Italian Medicines Agency (AIFA) has announced that, from 19 November 2026, ZIIHERA (zanidatamab) can be used through a monitoring registry for the indication admitted to reimbursement. The notice cites Determina Pres/1590, which entered into force following a notice in the Gazzetta Ufficiale no. 269 of 18 November 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: AIFA ↗

Article written by VigiEye from the official source (AIFA). AI-assisted; check the source before acting.